JP6868008B2 - 疼痛のための治療化合物及びその合成 - Google Patents

疼痛のための治療化合物及びその合成 Download PDF

Info

Publication number
JP6868008B2
JP6868008B2 JP2018511626A JP2018511626A JP6868008B2 JP 6868008 B2 JP6868008 B2 JP 6868008B2 JP 2018511626 A JP2018511626 A JP 2018511626A JP 2018511626 A JP2018511626 A JP 2018511626A JP 6868008 B2 JP6868008 B2 JP 6868008B2
Authority
JP
Japan
Prior art keywords
groups
group
alkyl
formula
acyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2018511626A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018527355A (ja
JP2018527355A5 (enExample
Inventor
リーベン ダニエル デコルト，バート
リーベン ダニエル デコルト，バート
コルネリス リュスヘル，ヤコブ
コルネリス リュスヘル，ヤコブ
コルネリス フランシスクス モンネ，メンノ
コルネリス フランシスクス モンネ，メンノ
Original Assignee
ヤンセン ファーマシューティカ エヌ．ベー．
ヤンセン ファーマシューティカ エヌ．ベー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ヤンセン ファーマシューティカ エヌ．ベー．, ヤンセン ファーマシューティカ エヌ．ベー． filed Critical ヤンセン ファーマシューティカ エヌ．ベー．
Publication of JP2018527355A publication Critical patent/JP2018527355A/ja
Publication of JP2018527355A5 publication Critical patent/JP2018527355A5/ja
Application granted granted Critical
Publication of JP6868008B2 publication Critical patent/JP6868008B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/18—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/10—Oxygen atoms acylated by aliphatic or araliphatic carboxylic acids, e.g. atropine, scopolamine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • C07D451/12—Oxygen atoms acylated by aromatic or heteroaromatic carboxylic acids, e.g. cocaine

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyridine Compounds (AREA)
JP2018511626A 2015-09-04 2016-09-01 疼痛のための治療化合物及びその合成 Expired - Fee Related JP6868008B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562214734P 2015-09-04 2015-09-04
US201562214727P 2015-09-04 2015-09-04
US62/214,727 2015-09-04
US62/214,734 2015-09-04
PCT/US2016/049893 WO2017040778A1 (en) 2015-09-04 2016-09-01 Therapeutic compound for pain and synthesis thereof

Publications (3)

Publication Number Publication Date
JP2018527355A JP2018527355A (ja) 2018-09-20
JP2018527355A5 JP2018527355A5 (enExample) 2018-11-22
JP6868008B2 true JP6868008B2 (ja) 2021-05-12

Family

ID=58188341

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2018511626A Expired - Fee Related JP6868008B2 (ja) 2015-09-04 2016-09-01 疼痛のための治療化合物及びその合成
JP2018511607A Expired - Fee Related JP6736661B2 (ja) 2015-09-04 2016-09-01 治療化合物及び合成
JP2018511601A Expired - Fee Related JP6736659B2 (ja) 2015-09-04 2016-09-01 疼痛のための治療化合物及びその合成
JP2018511605A Expired - Fee Related JP6736660B2 (ja) 2015-09-04 2016-09-01 疼痛のための治療化合物及びその合成
JP2018511670A Expired - Fee Related JP6639651B2 (ja) 2015-09-04 2016-09-01 疼痛のための治療化合物及びその合成

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018511607A Expired - Fee Related JP6736661B2 (ja) 2015-09-04 2016-09-01 治療化合物及び合成
JP2018511601A Expired - Fee Related JP6736659B2 (ja) 2015-09-04 2016-09-01 疼痛のための治療化合物及びその合成
JP2018511605A Expired - Fee Related JP6736660B2 (ja) 2015-09-04 2016-09-01 疼痛のための治療化合物及びその合成
JP2018511670A Expired - Fee Related JP6639651B2 (ja) 2015-09-04 2016-09-01 疼痛のための治療化合物及びその合成

Country Status (11)

Country Link
US (9) US9994572B2 (enExample)
EP (5) EP3344626B9 (enExample)
JP (5) JP6868008B2 (enExample)
CN (5) CN109153679B (enExample)
CA (5) CA2997541C (enExample)
DK (4) DK3344614T5 (enExample)
ES (4) ES2812233T3 (enExample)
IL (5) IL257732B (enExample)
MA (1) MA45011A (enExample)
TW (11) TWI713879B (enExample)
WO (5) WO2017040767A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6868008B2 (ja) * 2015-09-04 2021-05-12 ヤンセン ファーマシューティカ エヌ．ベー． 疼痛のための治療化合物及びその合成

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1469781A (en) * 1974-06-10 1977-04-06 Boehringer Sohn Ingelheim Production of scopine
US4232026A (en) * 1978-07-20 1980-11-04 Merck & Co., Inc. Diazaditwistanes, and pharmaceutical compositions for treating pain in warm blooded animals containing them
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4532244A (en) * 1984-09-06 1985-07-30 Innes Margaret N Method of treating migraine headaches
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5422354A (en) * 1990-07-23 1995-06-06 Pfizer Inc Quinuclidine derivatives
DE553264T1 (de) 1990-10-05 1994-04-28 Wayne M Barnes Thermostabile dna polymerase.
US6432976B1 (en) * 1999-10-29 2002-08-13 Merck & Co., Inc. 8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists
DE10050994A1 (de) * 2000-10-14 2002-04-18 Boehringer Ingelheim Pharma Neue als Arneimittel einsetzbare Anticholinergika sowie Verfahren zu deren Herstellung
ATE435862T1 (de) * 2003-05-28 2009-07-15 Theravance Inc Azabicycloalkanverbindungen als muscarinrezeptor antagonisten
CA2539811A1 (en) * 2003-10-15 2005-04-28 Targacept, Inc. Azabicycyclic compounds for relieving pain and treating central nervous system disorders
WO2007024814A1 (en) * 2005-08-22 2007-03-01 Targacept, Inc. HETEROARYL-SUBSTiTUTED DIAZATRICYCLOALKANES, METHODS FOR ITS PREPARATION AND USE THEREOF
US8735411B2 (en) * 2006-10-02 2014-05-27 Abbvie Inc. Macrocyclic benzofused pyrimidine derivatives
WO2008104955A1 (en) * 2007-02-28 2008-09-04 Ranbaxy Laboratories Limited Azoniatricyclo [3.3.1.0] nonane derivatives as muscarinic receptor antagonists
TW200840569A (en) 2007-03-13 2008-10-16 Targacept Inc Sub-type selective amides of diazabicycloalkanes
WO2009124755A1 (en) * 2008-04-08 2009-10-15 European Molecular Biology Laboratory (Embl) Compounds with novel medical uses and method of identifying such compounds
CN101768158B (zh) * 2010-01-04 2013-05-29 南昌弘益科技有限公司 噻托溴铵无水物及其制备方法
CN102579458A (zh) * 2012-03-08 2012-07-18 冀中能源峰峰集团有限公司总医院 缓解静点药物所致疼痛和防治静脉炎的药品配方
JP6102122B2 (ja) * 2012-08-24 2017-03-29 ソニー株式会社 画像処理装置および方法、並びにプログラム
BR112015006029B1 (pt) * 2012-09-18 2022-01-25 Heptares Therapeutics Limited Compostos aza bicíclicos como agonistas de receptor m1 muscarínicos, composição farmacêutica compreendendo ditos compostos e uso dos mesmos para tratar um distúrbio cognitivo ou distúrbio psicótico ou para tratar ou reduzir a gravidade de dores agudas, crônicas, neuropáticas ou inflamatórias
TW201444849A (zh) * 2013-03-13 2014-12-01 Janssen Pharmaceutica Nv 經取代的7-氮雜雙環類及其作為食慾激素受體調節劑之用途
TWI627174B (zh) * 2013-03-14 2018-06-21 比利時商健生藥品公司 Ｐ２ｘ７調控劑
KR20160115503A (ko) * 2015-03-27 2016-10-06 차의과학대학교 산학협력단 만성 골수성 백혈병 암 줄기세포의 성장 또는 증식 억제용 조성물 및 이의 스크리닝 방법
GB201505654D0 (en) * 2015-04-01 2015-05-13 Nordic Bioscience As Immunoassay for collagen type VI sequence
GB201505701D0 (en) * 2015-04-02 2015-05-20 Byotrol Plc Anti-microbial composition
JP6868008B2 (ja) * 2015-09-04 2021-05-12 ヤンセン ファーマシューティカ エヌ．ベー． 疼痛のための治療化合物及びその合成

Also Published As

Publication number Publication date
CA2997430A1 (en) 2017-03-09
CN108349934B (zh) 2021-10-22
ES2809703T3 (es) 2021-03-05
JP2018527356A (ja) 2018-09-20
DK3344627T5 (da) 2021-08-30
US10351566B2 (en) 2019-07-16
WO2017040770A1 (en) 2017-03-09
TW201811786A (zh) 2018-04-01
ES2812233T9 (es) 2022-02-18
DK3344627T3 (da) 2020-07-20
EP3344614A1 (en) 2018-07-11
US20170066760A1 (en) 2017-03-09
ES2812233T3 (es) 2021-03-16
US10040796B2 (en) 2018-08-07
ES2807901T3 (es) 2021-02-24
WO2017040778A1 (en) 2017-03-09
EP3344614B9 (en) 2021-07-28
IL257735A (en) 2018-04-30
JP2018527355A (ja) 2018-09-20
CA2997541C (en) 2022-01-11
IL257732B (en) 2020-11-30
TW201833110A (zh) 2018-09-16
DK3344626T5 (da) 2021-09-06
US10351565B2 (en) 2019-07-16
WO2017040764A1 (en) 2017-03-09
WO2017040772A9 (en) 2019-03-07
CA2997543A1 (en) 2017-03-09
CA2997543C (en) 2022-07-19
US10040795B2 (en) 2018-08-07
ES2808048T3 (es) 2021-02-25
IL257737B (en) 2022-10-01
ES2809703T9 (es) 2022-01-24
TWI683815B (zh) 2020-02-01
US20170066769A1 (en) 2017-03-09
US9994572B2 (en) 2018-06-12
EP3344627B1 (en) 2020-07-01
TW201722955A (zh) 2017-07-01
EP3344628B1 (en) 2020-07-15
US10766898B2 (en) 2020-09-08
US20180327406A1 (en) 2018-11-15
TWI654188B (zh) 2019-03-21
CN108495854B (zh) 2021-10-15
TWI686393B (zh) 2020-03-01
TW201722953A (zh) 2017-07-01
IL257737B2 (en) 2023-02-01
TWI672303B (zh) 2019-09-21
TWI636054B (zh) 2018-09-21
WO2017040772A1 (en) 2017-03-09
CN108290890A (zh) 2018-07-17
MA45011A (fr) 2021-06-02
CN109071540A (zh) 2018-12-21
JP6736661B2 (ja) 2020-08-05
DK3344614T5 (da) 2021-08-30
CA2997430C (en) 2021-05-11
US20170066768A1 (en) 2017-03-09
JP6736660B2 (ja) 2020-08-05
CA2997501C (en) 2022-05-10
TW201722954A (zh) 2017-07-01
TWI695836B (zh) 2020-06-11
DK3344628T3 (da) 2020-08-03
CA2997541A1 (en) 2017-03-09
US20170066770A1 (en) 2017-03-09
TWI641608B (zh) 2018-11-21
EP3344614A4 (en) 2019-03-27
ES2808048T9 (es) 2022-02-01
JP2018526388A (ja) 2018-09-13
TWI713879B (zh) 2020-12-21
CN109071540B (zh) 2021-06-04
EP3344628A1 (en) 2018-07-11
CN108495854A (zh) 2018-09-04
CA2997545A1 (en) 2017-03-09
EP3344626B9 (en) 2021-08-11
IL257735B (en) 2022-01-01
US20180291024A1 (en) 2018-10-11
TW201843153A (zh) 2018-12-16
EP3344614B1 (en) 2020-07-08
US20190112311A1 (en) 2019-04-18
TW201819381A (zh) 2018-06-01
IL257734B (en) 2021-07-29
TW201716409A (zh) 2017-05-16
CA2997501A1 (en) 2017-03-09
DK3344626T3 (da) 2020-07-27
EP3344627A1 (en) 2018-07-11
JP2018531907A (ja) 2018-11-01
IL257734A (en) 2018-04-30
US10358448B2 (en) 2019-07-23
DK3344628T5 (da) 2021-07-26
EP3344627B9 (en) 2021-08-04
EP3344627A4 (en) 2019-03-27
EP3344626A1 (en) 2018-07-11
CN108349934A (zh) 2018-07-31
EP3344629A1 (en) 2018-07-11
US20170066767A1 (en) 2017-03-09
TWI707854B (zh) 2020-10-21
US20180327405A1 (en) 2018-11-15
EP3344626B1 (en) 2020-07-08
CA2997545C (en) 2022-01-11
EP3344626A4 (en) 2019-03-27
WO2017040767A1 (en) 2017-03-09
IL257740A (en) 2018-04-30
JP6736659B2 (ja) 2020-08-05
CN109153679B (zh) 2022-04-08
TWI663167B (zh) 2019-06-21
CN109153679A (zh) 2019-01-04
TW201835082A (zh) 2018-10-01
US10155762B2 (en) 2018-12-18
EP3344628A4 (en) 2019-03-27
EP3344628B9 (en) 2021-06-30
JP2018526387A (ja) 2018-09-13
CN108290890B (zh) 2021-08-06
TW201920176A (zh) 2019-06-01
TWI639597B (zh) 2018-11-01
US10040797B2 (en) 2018-08-07
EP3344629A4 (en) 2019-03-27
JP6639651B2 (ja) 2020-02-05
IL257732A (en) 2018-04-30
IL257737A (en) 2018-04-30
TW201722951A (zh) 2017-07-01
ES2807901T9 (es) 2022-01-31
DK3344614T3 (da) 2020-07-27

Similar Documents

Publication Publication Date Title
JP6868008B2 (ja) 疼痛のための治療化合物及びその合成

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181015

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20181015

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190718

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190806

RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20190819

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20191226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200206

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200526

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200603

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200728

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201028

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201225

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210128

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210330

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210409

R150 Certificate of patent or registration of utility model

Ref document number: 6868008

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees